Status:
COMPLETED
The Crosstalk Between Calcium-sensing Receptor Signaling and Endocannabinoid System in Primary Hyperparathyroidism
Lead Sponsor:
Insel Gruppe AG, University Hospital Bern
Conditions:
Primary Hyperparathyroidism
Eligibility:
All Genders
18+ years
Brief Summary
Despite the strong association of hyperparathyroidism with arachidonic acid related lipid signals, little research has been performed over the years. A better understanding of the link between arachid...
Eligibility Criteria
Inclusion
- Age ≥ 18 years
- Primary hyperparathyroidism with planned surgery
- Written informed consent
Exclusion
- Age \<18 years
- Secondary/tertiary hyperparathyroidism
- Renal insufficiency
- Participant is pregnant
- Participant is incapable of giving an informed consent
Key Trial Info
Start Date :
February 1 2019
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
July 31 2022
Estimated Enrollment :
90 Patients enrolled
Trial Details
Trial ID
NCT03831620
Start Date
February 1 2019
End Date
July 31 2022
Last Update
January 26 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Department of visceral surgery and transplant surgery, Berne University Hospital
Bern, Switzerland, 3010